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SUMMARY
N6-methyl-adenosine (m6A) is the most abundant modification on messenger RNAs and is linked 
to human diseases, but its functions in mammalian development are poorly understood. Here we 
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reveal the evolutionary conservation and function of m6A by mapping the m6A methylome in 
mouse and human embryonic stem cells. Thousands of messenger and long noncoding RNAs 
show conserved m6A modification, including transcripts encoding core pluripotency transcription 
factors. m6A is enriched over 3′ untranslated regions at defined sequence motifs, and marks 
unstable transcripts, including transcripts turned over upon differentiation. Genetic inactivation or 
depletion of mouse and human Mettl3, one of the m6A methylases, led to m6A erasure on select 
target genes, prolonged Nanog expression upon differentiation, and impaired ESC’s exit from self-
renewal towards differentiation into several lineages in vitro and in vivo. Thus, m6A is a mark of 
transcriptome flexibility required for stem cells to differentiate to specific lineages.
INTRODUCTION
Reversible chemical modifications on messenger RNAs have emerged as prevalent 
phenomena that may open a new field of “RNA epigenetics”, akin to the diverse roles that 
DNA modifications play in epigenetics (reviewed by (Fu and He, 2012; Sibbritt et al., 
2013)). N6-methyl-adenosine (m6A) is the most prevalent modification of mRNAs in 
somatic cells, and dysregulation of this modification has already been linked to obesity, 
cancer, and other human diseases (Sibbritt et al., 2013). m6A has been observed in a wide 
range of organisms, and the methylation complex is conserved across eukaryotes. In 
budding yeast, the m6A methylation program is activated by starvation and required for 
sporulation. In Arabidopsis thalania, the methylase responsible for m6A modification, 
MTA, is essential for embryonic development, plant growth and patterning, and the 
Drosophila homolog IME4 is expressed in ovaries and testes and is essential for viability 
(reviewed in (Niu et al., 2013)).
While m6A has been suggested to affect almost all aspects of RNA metabolism, the 
molecular function of this modification remains incompletely understood (Niu et al., 2013). 
Importantly, m6A modification(s) are reversible in mammalian cells. Two members of the 
alpha ketoglutarate-dependent dioxygenases protein family, fat-mass and obesity associated 
protein (FTO) and ALKBH5 have been shown to act as m6A demethylases (Jia et al., 2011; 
Zheng et al., 2013). Manipulating global m6A levels has implicated m6A modifications in a 
variety of cellular processes including nuclear RNA export, control of protein translation 
and splicing (reviewed in (Meyer and Jaffrey, 2014)). Recently, m6A modification has been 
suggested to play a role in controlling transcript stability as YTH domain family of “reader” 
proteins specifically bind m6A sites and recruit the transcripts to RNA decay bodies (Kang 
et al., 2014; Wang et al., 2014a).
Whereas the DNA methylome undergoes dramatic reprogramming during early embryonic 
life, the developmental origins and functions of m6A in mammals are incompletely 
understood. Furthermore, the degree of evolutionary conservation of m6A sites is not known 
in ESCs. To date, the functions of m6A in mammalian cells have only been examined by 
RNAi knockdown. Depletion of METTL3 and METTL14 in human cancer cell lines led to 
decreased cell viability and apoptosis, leading to the interpretation that m6A is important for 
cell viability (Dominissini et al., 2012; Liu et al., 2014). A recent study reported that 
depletion of Mettl3 inhibited mouse ESC proliferation and led to ectopic differentiation 
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(Wang et al., 2014b). Here we assess the conservation of the m6A methylome at the level of 
gene targets and function in mouse and human ESCs. We report the consequences of genetic 
ablation of Mettl3 in mouse ESCs (mESCs) as well as depletion of METTL3 in human 
ESCs (hESCs). These experiments led to the unexpected finding that m6A and Mettl3 in 
particular are not required for ESC growth but are required for stem cells to adopt new cell 
fates.
RESULTS
Thousands of mESC transcripts bear m6A
To understand the role of the m6A RNA modification in early development, we mapped the 
locations of m6A modification across the transcriptome of mouse (mESC) and human 
(hESC) embryonic stem cells by m6A RIP-seq as described. (Dominissini et al., 2012; 
Meyer et al., 2012) (Methods). For each experiment, libraries were built for multiple 
biological replicates and concordant peaks for each experiment were used for subsequent 
bioinformatic analyses.
In mESCs, m6A-seq revealed a total of 9754 peaks in 5578 transcripts (average 2 peaks per 
transcript), including 5461 mRNAs (of 9923 mRNAs) and 117 lncRNAs. Due to the lower 
expression levels of lncRNA as a class, our approach likely underestimates the fraction of 
modified noncoding transcripts (Table S1). Thus, thousands of mESC transcripts, including 
mRNAs and lncRNAs, are m6A modified.
m6A in mRNAs of mESC core pluripotency factors
We found that mRNAs encoding the core pluripotency regulators in mESCs were modified 
with m6A (Dunn et al., 2014; Young, 2011), including Nanog, Klf4, Myc, Lin28, Med1, 
Jarid2 and Eed, whereas Pou5f1 (also known as Oct4) lacked m6A modification (Figure 1A, 
B). We confirmed m6A-seq results with independent m6A IP-qRT-PCR. (Figure S1A) and 
m6A-IP followed by Nanostring nCounter analysis (m6A-string) (Table S2). These 
validation results suggest that the m6A-seq data are accurate and robust. The top group of 
modified genes, based on degree of modification, was enriched for several functional 
groups, including: chordate embryonic development, embryonic development, gastrulation 
and cell cycle (Figure 1C). Thus, in mESCs, m6A targets include the ESC core pluripotency 
network and transcripts with dynamically controlled abundance during differentiation.
m6A location and motif in mESCs suggest a common mechanism shared with somatic 
cells
De novo motif analysis of mESC m6A sites specifically identified the previously described 
RRACU m6A sequence motif in somatic cells (Figure 1D, S1B) (reviewed in (Meyer and 
Jaffrey, 2014)). Furthermore, like somatic cells, m6A sites in mESC are significantly 
enriched near the stop codon and beginning of the 3′ UTR of protein coding genes (Figure 
1E and 1F), as previously described for somatic mRNAs. Although the largest fraction of 
m6A sites was within the coding sequence (CDS, 35%), the stop codon neighborhood is 
most enriched, comprising 33% of m6A sites while representing 12% of the motif 
occurrence. In genes with only one modification site, this bias is even more pronounced 
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(Figure 1F). Comparison of transcript read coverage between input and wild type revealed 
no bias for read accumulation around the stop codon in the input sample (Figure S1C).
In addition to the last exon, which often includes the stop codon and 3′-UTR, we found a 
strong bias for m6A modification occurring in long internal exons (median exon length of 
737bp vs. 124 bp; P<2.2×10−16; two-sided Wilcoxon test), even when the number of peaks 
per exon was normalized for exon length or motif frequency (Figure S1D–F). These results 
suggest the possibility that processing of long exons is coupled mechanistically to m6A 
targeting through as yet unclear systems and/or that m6A modification itself may play a role 
in controlling long exon processing. The topological enrichment of m6A peaks surrounding 
stop codons in mRNAs is a poorly understood aspect of the m6A methylation system. We 
sought to understand if there was a topological enrichment or constraint on m6A 
modification in non-coding RNAs (ncRNAs), which lack stop codons. We parsed both 
classes of RNAs with three or more exons into three normalized bins including the 1st, all 
internal and last exon. We observed an enrichment of m6A near the last exon-exon splice 
junction for both coding and ncRNAs and toward 3′ end of single-exon genes (Figure 1G, 
S1G–H), suggesting that the 3′ enrichment of m6A peaks can occur independently of 
translation or splicing. Together, the location and sequence features we identified in mESCs 
suggest a mechanism for m6A deposition that is similar if not identical in somatic cells.
m6A is a mark for RNA turnover
We next tested if transcript levels are correlated with the presence of m6A modification. 
Comparison of m6A enrichment level versus the absolute abundance of RNAs revealed no 
correlation between level of enrichment and gene expression (Figure 1H). A separate, 
quartile based analysis found a higher percentage of m6A-modified transcripts in the middle 
quartiles of transcript abundance (Figure S1I). Thus, our analysis suggests that m6A 
modification is not simply a random modification that occurs on abundant cellular 
transcripts; rather, m6A preferentially marks transcripts expressed at a medium level.
To further define potential mechanisms of m6A function, we asked whether m6A-marked 
transcripts differ from unmodified transcripts at the level of transcription, RNA decay, or 
translation by leveraging published genome-wide datasets in mESCs. RNA polymerase II 
occupancy at the promoters encoding both unmodified and m6A-marked RNAs is similar 
(Figure S1J). In contrast, m6A-marked transcripts had significantly shorter RNA half-life — 
2.5 hours shorter on average (p= < 2.2−16, Figure 1I), and increased rate of mRNA decay 
(average decay rate of 9 min vs. 5.4 min for m6A vs. unmodified, p= < 2.2−16). m6A 
modified transcripts have slightly lower translational efficiency than unmodified transcripts 
(1.32 vs. 1.51, respectively) (Ingolia et al., 2011) (Figure S1K). These results suggest that 
m6A is a chemical mark associated with transcript turnover.
Mettl3 knockout decreases m6A and promotes ESC self-renewal
To understand the role of m6A methylation in ESC biology, we chose to inactivate Mettl3, 
encoding one of the components of the m6A methylase complex. To date no genetic study of 
Mettl3 has been performed to rigorously define its requirement for m6A modification, as all 
studies have relied on knock down. We targeted Mettl3 by CRISPR-mediated gene editing, 
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and generated several homozygous Mettl3 Knockout (KO) mESC lines. DNA sequencing 
confirmed homozygous stop codons that terminate translation within the first 75 amino 
acids, and immunoblot analysis confirmed the absence of Mettl3 protein (Figure 2A, Figure 
S2A). Two dimensional thin layer chromatography (2D-TLC) showed a significant (~60%) 
but incomplete reduction of m6A in Mettl3 KO mESC (Figure 2B and Figure S2B). 
Contrary to a recent publication (Wang et al., 2014b), Mettl3 KO slightly reduced but did 
not prevent the stable accumulation of Mettl14 (Figure S2C). These experiments provide 
formal genetic proof that Mettl3 is a major, but not the sole, m6A methylase in mESC.
Contrary to the expectation in the literature, the Mettl3 KO mESCs are viable and 
surprisingly demonstrated improved self-renewal. Mettl3 KO mESCs could be maintained 
indefinitely over months and exhibited low levels of apoptosis, similar to wild type mESCs, 
as judged by PARP cleavage and Annexin V flow cytometry (Figure 2A, Figure S2D). We 
next asked whether Mettl3 KO affected the ability of stem cells to remain pluripotent. Mettl3 
KO mESC colonies were consistently larger than WT ESCs, and retained the round, 
compact ESC colony morphology with intense alkaline phosphatase staining comparable to 
wild type colonies as well as uniform expression of Nanog and Oct4 (Figure 2C, 2D, 2E, 
Figure S2E and data not shown). Quantitative cell proliferation assay confirmed the 
increased proliferation rate of KO over WT mESCs (Figure 2F). These observations suggest 
that Mettl3 KO enables enhanced mESC self-renewal. To rule out potential off-target effects 
from CRISPR-mediated gene targeting, we used an orthogonal approach to knockdown 
Mettl3 in mESCs. Two independent short hairpin RNAs (shRNAs) knocked down Mettl3 to 
~20% (Figure S2F). 2D-TLC showed a ~40% loss of m6A in poly(A) RNAs (Figure S2G), 
and apoptosis assays confirmed lack of cell death induction. Importantly, Mettl3 depletion 
also increased mESC proliferation compared to control shRNA for one hairpin (Figure 
S2H). Thus, two independent approaches confirm that Mettl3 inactivation enhanced self-
renewal of ESCs.
Mettl3 KO blocks directed differentiation in vitro and teratoma differentiation in vivo
These findings, coupled with the observation that modified genes tend to have a shorter half-
life, suggest that Mettl3, and by extension m6A, is needed to fine-tune and limit the level of 
many ESC genes, including pluripotency regulators. Since Mettl3 KO cells are capable of 
self-renewal, we tested their capacity for directed differentiation in vitro toward two 
lineages: cardiomyocytes (CM) and the neural lineage. While the WT cells were able to 
generate beating CM (~50% of colonies), only ~3% of Mettl3 KO colonies of two 
independent clones produced beating CMs. Furthermore, differentiated colonies of Mettl3 
KO cells retained high levels of Nanog expression but lacked expression of the CM 
structural protein Myh6, reflecting a larger number of cells that failed to exit the mESC 
program in the mutant cells. (Figure 3A and Supplemental Video 1 and 2). Similarly, upon 
directed differentiation to the neural lineage, we observed a marked difference between the 
ability of the two cells types to differentiate. To assay for neural differentiation we stained 
for Tuj1, a beta-3 tubulin expressed in mature and immature neurons. While ~53% of wild 
type colonies had Tuj1+ projections, less than 6% of Mettl3 KO colonies had Tuj1+ 
projections in both KO clones (Figure 3B). Additionally, differentiated Mettl3 KO cells 
showed an impaired ability to repress Nanog and activate Tuj1 mRNA (Figure 3B). To 
Batista et al. Page 5
Cell Stem Cell. Author manuscript; available in PMC 2015 December 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
confirm the role of Mettl3 in mESC differentiation in vivo, we injected Mettl3 KO or wild 
type cells subcutaneously into the right or left flank respectively, of SCID/Beige mice (n=5). 
Both wild type and Mettl3 KO cells formed tumors consistent in morphology with 
teratomas. Mutant tumors tended to be larger, in accordance with mutant cell growth curves 
observed in vitro (Figure 3C). Histological analysis of H&E stained tumor sections revealed 
consistent differences between the two populations. While both groups of cells formed 
teratomas that contained some degree of differentiation into all three germ layers, the 
teratomas derived from KO cells were predominantly composed of poorly differentiated 
cells with very high mitotic indices and numerous apoptotic bodies, whereas wild type cells 
differentiated predominantly into neuroectoderm (Figure 3D). Analysis of adjacent sections 
revealed that the mutant teratomas have markedly higher staining of proliferation marker 
Ki67 and ESC protein Nanog, which highlight the poorly differentiated cells (Figure 3E, 3F 
and Figure S3A). Mettl3 KO tumors had higher levels of Nanog, Oct4 and Ki67 mRNAs and 
lower levels of Tuj1, Myh6 and Sox17 mRNAs (Figure S3B). These results suggest that 
insufficient m6A leads to a block in ESC differentiation and persistence of a stem-like, 
highly proliferative state.
Mettl3 target genes in mESCs
The incomplete loss of bulk m6A in Mettl3 KO may result because Mettl3 is solely 
responsible for the methylation of a subset of genes or sites and/or Mettl3 functions in a 
redundant fashion with another methylase on all m6A-modified genes. To distinguish these 
possibilities, we mapped the m6A methylome in Mettl3 KO cells. Comparison of the 
methylomes of wild type vs. Mett3 KO mESCs revealed a global loss of methylation across 
m6A sites identified in wild type (Figure 4A). We detected changes in 3739 sites (in 3122 
genes), including modification sites in Nanog mRNA. Thus, this unbiased analysis 
suggested a set of targets that rely more exclusively on Mettl3, including Nanog and other 
pluripotency mRNAs (Figure 4B and 4C) (Table S1). Gene Set Enrichment Analysis 
confirmed that Mettl3-target genes significantly overlap functional gene sets important for 
pluripotency, including targets of Ctnnb1 (4.43 ×10−6), targets of Smad2 or Smad3 (1.03 
×10−16), targets of Myc (9.20 ×10−10), targets of Sox2 (4.75 ×10−8), and targets of Nanog 
(7.18 × 10−8) (Figure 4C), and include five of eleven core ESC regulators such as Nanog, 
Rlf1, Jarid2, and Lin28 (Figure 4D). Independent validation by m6A RIP followed by 
Nanostring detection confirmed loss of m6A in Nanog and other mRNAs in KO vs. wild 
type mESCs (Figure 4E). Further, following transcription arrest by flavopiridol treatment, 
Nanog mRNA showed delayed turnover in Mettl3 KO cells compared to wild type, 
consistent with a requirement for m6A in Nanog mRNA turnover (Figure 4F). However, 
RNA-seq analysis of Mettl3 KO cells revealed modest perturbations in mRNA steady state 
levels with only ~300 genes demonstrating significant changes over 1.5 fold. Collectively, 
these results suggest ESC genes are under Mettl3 control, and m6A impacts ESC biology.
Wide spread m6A modification of human ESCs
The identification of thousands of m6A sites raises the challenge of defining the functional 
importance of each and every one of the sites. We reasoned that evolutionary conservation 
provides a powerful and comprehensive metric of function. To this end, we mapped m6A 
sites in hESCs and during endoderm differentiation to elucidate the patterns and potential 
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conservation of m6A methylome (Figure 5A). In basal state hESCs (Time (T) = 0), m6A-seq 
identified 16943 peaks in 7871 genes representing 7530 coding and 341 non-coding RNAs. 
Upon differentiation towards endoderm (T = 48, “endoderm differentiation” thereafter), 
m6A-seq identified 15613 m6A peaks in 7195 genes representing 6909 coding and 286 non-
coding RNAs (Table S3). As shown in Figure 5B, 11322 peaks (6004 genes) were common 
between the undifferentiated and differentiated hESCs, while 5348 (3979 genes) vs. 4087 
peaks (3024 genes) were unique, respectively.
Many master regulators of hESC maintenance and differentiation are modified with m6A
As we observed for mESC, transcripts encoding many hESC master regulators, including 
human NANOG, SOX2, and NR5A2, were m6A modified. Like mESC, the transcripts for 
OCT4 (POUF51) in hESC did not harbor an m6A modification (Figure 5D). These results 
show that in both organisms the core-pluripotency/maintenance genes are under the 
regulatory influence of the m6A pathway. We also identified human specific lncRNAs with 
known roles in hESC maintenance such as LINC-ROR and MEGAMIND/TUNA to contain 
m6A modification(s) (Figure 5D; Figure S4A) (Lin et al., 2014; Loewer et al., 2010). Upon 
induction of differentiation, we observed transcripts encoded by several key regulators of 
endodermal differentiation also to have m6A modifications including EOMES and FOXA2 
(Figure 5D). Gene ontology (GO) analyses of methylated genes in undifferentiated hESCs, 
and after endodermal differentiation, were significantly enriched in biological functions such 
as regulation of transcription (FDR=1.2×10−14), chordate embryonic development 
(FDR=1.1×10−4), and regulation of cell morphogenesis (FDR=0.01).
Upon differentiation toward endoderm, 1356 peaks in 1137 genes showed quantitative 
differences of at least 1.5 fold in m6A intensity, after normalization for input transcript 
abundance (Figure 5E and 5F, Table S4). The majority of these differential m6A sites 
represented quantitative differences at existing sites (i.e. 59.1% of the peaks were called in 
both time points), rather then state-specific de novo appearance or erasure of modification 
(Figure 5G). This is consistent with the observation that 74.9% of sites in the hESCs 
overlapped those observed in HEK293T data (Meyer et al., 2012) and the minimal changes 
in m6A sites observed in a recent survey of m6A pattern across cell types (Schwartz et al., 
2014). We suggest that transcripts exhibit dynamic differential peak m6A methylation 
intensity largely at “hard wired sites” during differentiation under the conditions examined 
and when compared to other tissue types.
Conserved features of m6A modifications spanning different species
We found that three salient features of the m6A methylome are conserved in hESCs. First, 
m6A sites in hESCs are also dominated by the RRACU motif seen in mESC and somatic 
cells (Dominissini et al., 2012; Meyer et al., 2012) (Figure 5C). There was also a strong 
preference of targeting long-internal exons at the RRACU motif even after normalizing for 
exon length and number of m6A motifs (Figure 5H). Second, there was a significant 
enrichment in m6A peaks at 3′ end of transcripts, near the stop codon of coding genes or the 
last exon in non-coding RNAs (Figure 5I, Figure S4B, S4C and S4D). Furthermore, the 
topology of m6A modification is preserved upon endodermal differentiation (Figure 5I). As 
in mESCs, moderate to lowly expressed genes have higher probability of becoming 
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methylated (Figure S4E). Lastly, hESC m6A is not correlated with transcription rate as 
judged by GRO-seq (Sigova et al., 2013), but is strongly anti-correlated with measured 
mRNA half-life in human pluripotent cells (Neff et al., 2012), strongly suggesting that m6A 
modification also marks RNA turnover in hESCs (Figure 5J, Figure S4F and S4G).
Evolutionary conservation and divergence of the m6A epi-transcriptomes of human and 
mouse ESCs
Previous studies suggested significant conservation of m6A modified genes between mouse 
and human in somatic cell types, but the comparisons are limited by non-matched tissue 
types (Dominissini et al., 2012; Meyer et al., 2012). We were thus interested in examining 
the evolutionary conservation of human and mouse ESC m6A methylomes. At the gene 
level, 69.4% (3609 of 5204) of hESC genes are also m6A modified in the orthologus mouse 
gene (p-value= 8.3×10−179; Fisher exact test) (Figure 6A; Table S5). Furthermore, we 
identified 632 conserved m6A peak sites (46.1%) between hESCs and mESCs (Table S6). 
Notably, conserved sites tended to have higher m6A peak intensities compared to m6A peak 
sites that are not conserved (Figure 6B and 6C, p-values=1.3×10−15 and 8.7×10−23 for hESC 
or mESC, respectively; Wilcoxon test). Commonly methylated genes can demonstrate m6A 
modification sites at identical site(s) such as GLI1, similar but not identical locations such as 
SOX2, or m6A site at different exons, such as CHD6 (Figure 6D, 6E and 6F, Table S4). Our 
data thus reveal a substantial overlap at the gene level, suggesting broad functional 
significance of m6A modification in ESCs in both species. At the same time, we also 
observed numerous species-specific m6A patterns that may contribute to specific aspects of 
ESC biology (Schnerch et al., 2010).
METTL3 is required for hESC differentiation
To address the function of m6A in hESCs, we generated hESC colonies with stable 
knockdown of METTL3 and shRNA control (Figure 7A). Knockdown of METTL3 in 
hESCs resulted in reduction in METTL3 mRNA levels and reduction in m6A level (Figure 
7B, 7C and Figure S5B, S5C). METTL3-depleted hESCs could be stably maintained, 
suggesting the dispensability of METTL3 for hESC self-renewal or viability. Strikingly, 
differentiation of METTL3-depleted hESCs into neural stem cells (NSCs) by dual inhibition 
of SMAD signaling, using Dorsomorphin and SB-431542 revealed a block in neuronal 
differentiation (Methods). While 44% (+/−3.5% s.d.) of the control cells were Sox1 positive, 
only 10% (+/−3.1% s.d) of the METTL3-depleted were Sox1 positive (Figure S5A).
Similarly, knockdown of METTL3, in three independently generated hES colony clones 
selected for METTL3 knockdown, led to a profound block in endodermal differentiation at 
day 2 and day 4 based on failure to express the endoderm markers EOMES and FOXA2 
compared to either two shRNA control colony clones (Figure 7D) or wildtype hESCs 
(Figure S5D). Consistently, METTL3-depleted ESCs retain high levels of expression of the 
master regulators NANOG and SOX2 throughout the differentiation time course in contrast 
to their diminishing expression in wild type cells (Figure 7E and S5E). These results indicate 
that METTL3 and m6A control differentiation of human embryonic stem cells.
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DISCUSSION
m6A methylome in ES cells
Our analysis of the ESC m6A methylome in mouse and human cells reveals extensive m6A 
modification of ESC genes, including most key regulators of ESC pluripotency and lineage 
control. However, this observation does not mean that m6A is uniquely tied to the 
pluripotency network. Because m6A marks moderately expressed transcripts that need to be 
turned over in a timely fashion, such genes in ESCs likely include many regulators of 
pluripotency and lineage determination. The pattern and sequence motif associated with 
ESC m6A are similar if not identical to those previously reported in somatic cells, 
suggesting a single mechanism that deposits m6A modification in early embryonic life. This 
invariant mechanism for m6A contrasts with the complexity of 5-methyl-cytosine in DNA 
and histone lysine methylations that undergo extensive reprogramming with distinct rules in 
pluripotent vs. somatic cells.
We identified a general and conserved topological enrichment of m6A sites at the 3′ end of 
genes among single-exon and multi-exon mRNAs as well as ncRNAs. Thus, neither the stop 
codon nor the last exon-exon splice junction can alone explain the observed m6A topology 
in RNA. However, all species examined to date including Saccharomyces cerevisae and A. 
thalania exhibit a strong 3′ bias in m6A localization, suggesting an evolutionary constraint 
that may target the m6A modification to the 3′ ends of genes regardless of gene structure or 
coding potential. This bias may be achieved by preferential m6A methylases recruitment to 
3′ sites or preferential action of demethylases in upstream regions of the transcript. Although 
the role of demethylases cannot be excluded, the observation of 3′ end m6A bias in S. 
cerevisiae, which lacks known m6A demethylases argues against the latter mechanism (Bodi 
et al., 2012; Jia et al., 2011; Schwartz et al., 2013; Zheng et al., 2013). The functional 
importance of m6A location vs. its specific molecular outcome need to be addressed in 
future studies.
Mettl3 selectively targets mRNAs including pluripotency regulators
While several studies had approached Mettl3 function by RNAi knock down (Dominissini et 
al., 2012; Fustin et al., 2013; Liu et al., 2014; Wang et al., 2014b), genetic ablation of Mettl3 
KO allowed us to examine the true loss-of-function phenotypes. The importance of using 
definitive genetic models is highlighted by recent studies in the DNA methylation field 
where shRNA experiments led to mis-assigned functions of Ten-eleven translocation (TET) 
proteins that were later recognized in genetic knockouts (Dawlaty et al., 2013; Dawlaty et 
al., 2011). We found that both Mettl3 KO and depletion led to incomplete reduction of the 
global levels m6A in both mESCs and hESCs, demonstrating redundancy in m6A 
methylases. However, m6A profiling in Mettl3 KO cells revealed a subset of targets, 
approximately 33% of m6A peaks, that are preferentially dependent on Mettl3, and these 
included Nanog, Sox2, and additional pluripotency genes. A second m6A methylase, 
Mettl14, was described during the preparation of this manuscript.
RNAi knockdown of Mettl3 in somatic cancer cells led to apoptosis (Dominissini et al., 
2012), and one study reported ectopic differentiation of mESC with Mettl3 depletion (Wang 
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et al., 2014b). In contrast, we found that Mettl3 KO does not affect mESC cell viability or 
self-renewal, and in fact mESC renewed at an improved rate. The differences in phenotype 
observed could potentially be explained by different dependency on m6A modified RNAs in 
different cell types, acute versus chronic inactivation, or RNAi off target effects. m6A 
methylome analysis in different cell types with Mettl3 inactivation may shed light on these 
differences in the future.
Conservation of m6A methylome in mammalian ESCs
The conserved methylation patterns of many ESC master regulators and the shared 
phenotype observed upon inactivation of METTL3 suggest that METTL3 operates to control 
stem cell differentiation. It is known that human and mouse ESCs are not equivalent 
(Schnerch et al., 2010), and are cultured in different conditions. By focusing in on 
orthologous genes, we were able to catalog both shared and species-specific methylation 
sites. The observation that certain methylation sites are modified whenever a target 
transcript is expressed in both species, despite cell state or culture differences, argues that 
these modification events have been preserved under strong purifying selection during 
evolution. Our comparative genomic analyses also pave the way to further understand 
potential biological differences between mouse and human ESCs at the level of m6A 
epitranscriptome, given the unique patterns of some methylation sites between the species.
RNA “anti-epigenetics”: m6A as a mark of transcriptome flexibility
Stem cell gene expression programs need to balance fidelity and flexibility. On one hand, 
stem cell genes need sufficient stability to maintain self-renewal and pluripotency over 
multiple cell generations, but on the other hand, gene expression needs to change 
dynamically and rapidly in response to differentiation cues. It has been proposed that ESC 
gene expression programs are in constant flux between competing fates, and pluripotency is 
a statistical average (Loh and Lim, 2011; Montserrat et al., 2013; Shu et al., 2013). We 
found that mRNAs with m6A tend to have a shorter half-life, and Nanog and Sox2 mRNAs 
could not be properly down-regulated with differentiation in Mettl3-deficient mESC and 
hESC. However, Mettl3 deficiency has only modest effects on steady state gene expression, 
which could arise from the non-stoichiometric nature of the m6A modification. The 
application of methods that can determine level of modification of each RNA species will 
allow us to answer these questions (Harcourt et al., 2013; Liu et al., 2013). Mettl3 KO 
mESCs have enhanced self-renewal but hindered differentiation, concomitant with 
decreased ability to down regulate ESC mRNAs. WTAP, a conserved Mettl3 interacting 
partner from yeast to human cells (Horiuchi et al., 2013; Schwartz et al., 2014), is also 
required for endodermal and mesodermal differentiation (Fukusumi et al., 2008). The 
observed phenotypes in ESC and teratomas are all the more notable because we have 
significantly reduced but not eliminated m6A.
Our findings suggest a model where m6A serves as the necessary flexibility factor to counter 
balance epigenetic fidelity—a RNA “anti-epigenetics” (Figure 7F). m6A marks a wide range 
of transcripts, including ESC fate determinants to limit their level of expression, and ensure 
their continual degradation so that cells can rapidly transition between gene expression 
programs. In ESC, m6A is required for cells to rapidly exit the pluripotent state upon 
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differentiation. The inability to exit the stem cell state and continued proliferation upon 
insufficient m6A offers a potential explanation for the association of FTO with human 
cancers (Loos and Yeo, 2013). METTL3 depletion also leads to elongation of the circadian 
clock (Fustin et al., 2013), suggesting a role for m6A in resetting the transcriptome. In yeast, 
m6A is active during meiosis (Clancy et al., 2002), where diploid gene expression programs 
are reset to generate haploid offspring. We propose that m6A makes the transition between 
cell states possible by facilitating a reset mechanism between stages, as occurs in ESCs and 
likely other cell types. In contrast to epigenetic mechanisms that provide cellular memory of 
gene expression states, m6A enforces the transience of genetic formation – helping cells to 
forget the past and thereby embrace the future.
EXPERIMENTAL PROCEDURES
For full details, see Extended Experimental Procedure.
Mouse cell culture and differentiation
J-1 murine embryonic stem cells were grown under typical feeder free ES cell culture 
conditions. For cardiomyocyte formation, mESCs were differentiated in cardiomyocyte 
differentiation media and scored on day 12. For neuron formation, mESCs were 
differentiated in MEF and ITSFn medium and scored after 10 days in ITSFn medium. For 
the cell proliferation assay 5000 cells where cultured in 24 well plates and the assay 
performed according to the manufacturer’s protocol (MTT assay). For the single colony 
assays and Nanog staining, 1000 cells where cultured per well, on a six well plate. For 
alkaline phosphatase staining, cells were stained according to the manufacturer’s protocol 
(Vector Blue Alkaline Phosphatase Substrate Kit).
hESCs cell culture, transfection and differentiation
H1 (WA01) cells were cultured in feeder-free conditions as described (Sigova et al., 2013). 
Stable hESC lines were created that expressed shMETTL3 RNA or scrambled shRNA by 
transfecting hESCs with plasmids encoding shMETTL3 or scrambled shRNA and a 
puromycin resistance gene. Cells were treated with puromycin for six days beginning two 
days after transfection. For each shRNA, two independent puromycin-resistant colonies 
were picked and expanded. Endodermal differentiation was then induced by Activin A, as 
described (Sigova et al., 2013). Day 2 and Day 4 of differentiation were measured from the 
time that Activin was added. Puromycin was removed from the media one day prior to 
endodermal differentiation.
RNA m6A IP and m6A methylation IP RNA-sequencing analysis
Libraries generated with iCLIP adaptors where separated by barcode, and perfectly 
matching reads were collapsed. Sequencing reads were mapped using TopHat (Trapnell et 
al., 2009). A non-redundant mm9 transcriptome was assembled from UCSC RefSeq genes, 
UCSC genes, and predictions from (Ulitsky et al., 2011) and (Guttman et al., 2011). For 
human datasets, the Ensembl genes (release 64) was used. Search for enriched peaks was 
performed by scanning each gene using 100-nucleotide sliding windows, and calculating an 
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enrichment score for each sliding window (Dominissini et al., 2012). HOMER software 
package (Heinz et al., 2010) was used for de novo discovery of the methylation motif.
CRISPR-mediated Mettl3 knockout
gRNA sequences where chosen and designed a CRISPR design tool (Hsu et al., 2013). 
Plasmids for guide RNA were co-nucleofected, with a human codon optimized Cas9 
expression plasmid and a plasmid with a puromycine resistance cassette. Cells were plated 
at low density for single colony isolation and selected single colonies tested by western blot 
for loss of protein.
Determination of m6A levels
2D-TLC was performed as described by (Jia et al., 2011). For dot-blots, the indicated 
amounts of RNA were applied to the membrane and cross-linked by UV. The m6A primary 
antibody was added at a concentration of 1:500. The membrane was incubated with the 
secondary antibody and exposed to an auto-radiographic film. m6A RNA mass-spectrometry 
was performed as described in the Extended Experimental Procedures.
Dataset comparison
Mouse Pol II occupancy data, mRNA half life and Protein translation efficiency were 
obtained from (Ingolia et al., 2011; Rahl et al., 2010; Sharova et al., 2009). Plotting and 
statistical tests were performed in R. Multi-dimensional gene set enrichment analysis over 
DAVID Gene Ontology terms and stem cell gene sets (Wong et al., 2008) were performed 
using Genomica (Segal et al., 2003).
Teratoma generation and histopathology
Mettl3 wild type and mutant cells were subcutaneously injected into 8-week-old female 
SCID/Beige mice (Charles River). Four weeks after injection, the mice were euthanized and 
the tumors harvested. All animal studies were approved by Stanford University IACUC 
guidelines. For histological analysis, slides were stained with hematoxylin and eosin (H&E) 
or stained by immunohistochemistry (IHC) with VECTASTAIN ABC Kit and DAB 
Peroxidase Substrate Kit following the manufacturer’s instructions. Analyses were 
performed by a boarded veterinary pathologist (DMB).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Topology and characterization of m6A target genes
(A) UCSC Genome browser plots of m6A-seq reads along indicated mRNAs. Grey reads are 
from non-immunoprecipitated input libraries and red reads from anti-m6A 
immunoprecipitation libraries. The y-axis represents normalized number of reads. Blue thick 
boxes represent the open reading frame while the blue line represents the untranslated 
regions. See also Figure S1A and Table S1 and S2. (B) Model of genes involved in 
maintenance of stem cell state (adapted from Young et al., 2011). Red hexagons represent 
modified mRNAs. (C) Heatmap with log10 (p-vlaue) of gene set enrichment analysis for 
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m6A modified genes. (D) Sequence motif identified after analysis of m6A enrichment 
regions. See also Figure S1B, S1C. (E) Normalized distribution of m6A peaks across 5′ 
UTR, CDS and 3′UTR of mRNAs for peaks common to all samples. (F) Graphical 
representation of frequency of m6A peaks and methylation motifs in genes, divided into 5 
distinct regions. (G) Distribution of m6A peaks across the length of mRNAs (n=5070) and 
non-coding RNAs (n=51). See also Figure S1D, S1E, S1F, S1G and S1H. (H) Scatter plot 
representation of m6A enrichment score (on the X axis) and gene expression level (on the Y 
axis) for each m6A peak. See also Figure S1I. (I) Box plot representing the half-life for 
transcripts with at least one modification site and transcripts with no modification site 
identified. See also figure S1J and S1K.
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Figure 2. Characterization of Mettl3 knock out cells
(A) Western blot for Mettl3 and PARP in wild type and two cell lines with CRISPR induced 
loss of protein (DD: DNA damaging agent). Actin is used as loading control. See also Figure 
S2A. (B) m6A ratio determined by 2D-TLC in wild type and Mettl3 KO. Error bars 
represent standard deviation of 3 biological replicates in all panels. See also Figure S2B and 
S2C. (C) Alkaline phosphatase staining of wild type and Mettl3 knock out cells. See also 
Figure S2D and S2E. (D) Box plot representation of colony radius for wild type and Mettl3 
mutant cells. Experiments were performed in triplicate, with at least 50 colonies measured 
for each replicate. (E) Nanog staining of colonies of wild type and two cell lines with 
CRISPR induced loss of protein. (F) Cell proliferation assay of wild type and two cell lines 
with CRISPR induced loss of Mettl3 protein. See also Figure S2F, S2G and S2H.
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Figure 3. Mettl3 loss of function impairs ESC ability to differentiate
(A) Percentage of embryoid bodies with beating activity in Mettl3 KO and wild type control 
cells (right panel). Representative images of bodies stained for MHC and DAPI (center 
panel) and mRNA levels of Nanog and Myh6, measured by qRT-PCR, in Mettl3 KO cells in 
relation to wild type control cells. Error bars, standard deviation of 3 biological replicates in 
all panels. * represents p-value < 0.05, t-test (2 tailed). See also Movie S1 and S2. (B) 
Percentage of colonies with Tuj1 projections in Mettl3 KO and wild type control cells (right 
panel). Representative images of bodies stained for Tuj1 and DAPI (center panel) and 
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mRNA levels of Nanog and Tuj1, measured by qRT-PCR, in Mettl3 KO cells in relation to 
wild type control cells. * represents p-value < 0.05, t-test (2 tailed). (C) Weight differences 
between teratomas generated from wild type and Mettl3 knock out cells. Tumors are paired 
by animal (n=5). (D) Representative sections of teratomas stained with hematoxylin and 
eosin at low magnification. Bar=1000 μm. See also Figure S3A. (E and F) 
Immunohistochemistry with antibody against Ki67 (E) and with antibody against Nanog 
(F). Bar represents 100 μm. See also Figure S3B.
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Figure 4. Impact of loss of Mettl3 on the mESC methylome
(A) Cumulative distribution function of log2 peak intensity of m6A modified sites. (B) 
Sequencing read density for input (grey) vs. in m6A IP (red) for Nanog. Y-axis represents 
normalized number of reads. Gene model as in Figure 1A. (C) Heatmap representing IP 
enrichment values for peaks with statistically significant difference between wild type and 
Mettl3 mutant. Bar to the right represent genes in each dataset with a >1.5 fold decrease in 
IP enrichment values. (D) Model of genes involved in maintenance of stem cell state 
(adapted from Young et al., 2011), representing transcripts with loss of m6A modification in 
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Mettl3 −/− cells. (E) Percentage of input recovered after m6A IP measured by Nanostring 
for each mRNA. Error bars, standard deviation of 2 biological replicates. *, p-value < 0.05, 
t-test (2 tailed). (F) mRNA levels of Nanog and Oct4, measured by qRT-PCR, after PolII 
inhibition relative to untreated sample in wild type and Mettl3 KO cells. Error bars, standard 
deviation of 3 biological replicates. *, p-value < 0.05, t-test (2 tailed).
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Figure 5. m6A-seq profiling of hESC during endoderm differentiation
(A) m6A-seq was performed in resting (undifferentiated) human H1-ESCs (T0) and after 
48hrs of Activin A induction towards endoderm (mesoendoderm) (T48). (B) Venn diagram 
of the overlap between high-confidence T0 and T48 m6A peaks. The number of genes in 
each category is shown in parenthesis. See also Table S3 and S4. (C) Sequence motif 
identified after analysis of m6A enrichment regions. (D) UCSC Genome browser plots of 
m6A-seq reads along indicated RNAs. Grey reads are from non-immunoprecipitated control 
input libraries and red (T0) or blue (T48) reads are from anti-m6A immunoprecipitation 
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libraries. Y-axis represents normalized number of reads; X-axis is genomic coordinates. Key 
regulators of stem cell maintenance (left) and master regulators of endoderm differentiation 
(right) are represented. See also Figure S4A. (E) Scatterplot of m6A peak intensities 
between two different time points (T0 versus T48) of the same biological replicate with only 
“high-confidence” T0 or T48 specific peaks supported by both biological replicates 
highlighted. (F) UCSC Genome browser plots of m6A-seq reads along indicated mRNAs in 
undifferentiated (T0) versus differentiated cells (T48). The grey reads are from non-
immunoprecipitated control input libraries. The red and blue reads are from the anti-m6A 
RIP of T=0 and T=48 samples respectively. (G) Differential intensities of m6A peaks 
(DMPIs) identify hESC cell states T0 vs T48hrs. Z score scaled Log2 peak intensities of 
DMPIs are color-coded according to the legend. The peaks and samples are both clustered 
by average linkage hierarchical clustering using 1-Pearson correlation coefficient of log2 
peak intensity as the distance metric. (H) Number of peaks per exon normalized by the 
number of motifs (on sense strand) in the exon. The error bars represent standard deviations 
from 1000 times of bootstrapping. (I) The normalized distribution of m6A peaks across the 
5′UTR, CDS, and 3′UTR of mRNAs for T0 and T48 m6A peaks. See also Figure S4B, S4C 
and S4D. (J) Box plot representing the half-life for transcripts, with transcripts separated 
according to enrichment score. See also Figure S4E, S4F and S4G.
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Figure 6. Evolutionary conservation and divergence of the m6A epi-transcriptomes of human 
and mouse ESCs
(A) Venn diagram showing a 62% overlap between methylated genes in M. musculus 
(purple) and H. sapiens (red) embryonic stem cells (p value= 3.5 × 10−92; Fisher exact test). 
See also Table S5 and S6. (B) The m6A peaks that could be mapped to orthologous genomic 
windows between mouse and human were identified. The intensities of m6A-seq signals in 
human and mouse ESCs were shown for m6A peaks found to be unique in mouse (blue), 
unique in human (red), and conserved between human and mouse (black). (C) Boxplot of 
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peak intensities of m6A sites conserved (“common”) or not conserved (“specific”) in mouse 
and human ESCs. (p values=1.3×10−15 and 8.7×10−23 respectively). (D to F) UCSC 
Genome browser plots of m6A-seq reads along indicated mRNAs. The grey reads are from 
non-immunoprecipitated control input libraries and the purple and red reads are from the 
anti-m6A RIP of mESCs and hESCs (T0) respectively. (D) Mouse-specific m6A 
modifications are represented. (E) Human-specific m6A modifications ESCs are 
represented. (F) Conserved m6A modifications at gene and site level are represented. Genes 
such CHD6 have a conserved m6A peak location at its 3′UTR as well as mouse and human 
specific m6A peaks at conserved but distinct exons.
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Figure 7. METTL3 is required for normal human ESC endoderm differentiation. Model of 
METTL3 function(s)
(A) hESC cells were transfected with anti-METTL3 shRNA (KD) as well control shRNA 
and stable hESC colonies were obtained after drug selection. Two independent clones were 
subjected to endodermal differentiation with Activin A and examined at various indicated 
time points. A schematic of the trends of gene expression for indicated markers of stem 
maintenance and endoderm differentiation is also shown. See also figure S5A. (B) Levels of 
METTL3 mRNA in hESC cells with control shRNA versus anti-METTL3 shRNA (KD) 
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across the three indicated time points during endodermal differentiation (n=2 independent 
generated ES cell knockdown and control clones shown). In all panels, Error bars represent 
standard deviation across 3 replicates per time point; *, p value<0.05 t-test (2 tailed) 
between different clones. See also Figure S5B. (C) Anti-m6A dot blot was performed on 10x 
fold dilutions of polyA selected RNA from hESC cells derived from control shRNA versus 
anti-METTL3 shRNA clones. See also Figure S5C. (D and E) mRNA levels of endodermal 
and stem maintenance/marker genes. qRT-PCR was performed on indicated genes and time 
points (n=2 independently generated ES cell knockdown and control clones shown). See 
also Figure S5D. (F) Model: m6A marks transcripts for faster turn-over. Upon transition to 
new cell fate, m6A marked transcripts are readily removed to allow the expression of new 
gene expression networks. In the absence of m6A, the unwanted presence of transcripts will 
disturb the proper balanced required for cell fate transitions.
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